Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18,021 | 22,452 | 27,700 | 11,650 | 12,828 |
| Receivables | 90 | 27 | 27 | 97 | 70 |
| TOTAL | $18,410 | $23,149 | $28,121 | $12,193 | $13,426 |
| Non-Current Assets | |||||
| PPE Net | 268 | 295 | 320 | 338 | 7 |
| Intangibles | 421 | 431 | 442 | 452 | 463 |
| TOTAL | $689 | $727 | $761 | $790 | $470 |
| Total Assets | $19,099 | $23,875 | $28,883 | $12,984 | $13,895 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 316 | 2,002 | 1,050 | 1,697 | 824 |
| Accrued Expenses | 1,639 | 892 | 820 | 841 | 162 |
| Other current liabilities | 6,878 | 6,732 | 8,070 | N/A | N/A |
| TOTAL | $9,045 | $10,217 | $10,250 | $2,866 | $1,119 |
| Non-Current Liabilities | |||||
| TOTAL | $175 | $197 | $219 | $241 | $0 |
| Total Liabilities | $9,220 | $10,414 | $10,469 | $3,107 | $1,119 |
| Shareholders' Equity | |||||
| Common Shares | 58,079 | 57,412 | 56,784 | 45,256 | 42,552 |
| Retained earnings | -60,480 | -55,771 | -49,831 | -46,335 | -40,016 |
| Other shareholders' equity | 12,280 | 11,820 | 11,460 | 10,955 | 10,240 |
| TOTAL | $9,879 | $13,461 | $18,413 | $9,877 | $12,776 |
| Total Liabilities And Equity | $19,099 | $23,875 | $28,883 | $12,984 | $13,895 |